NCNA vs. EFTR, ADXN, OBSV, BNOX, CYCN, VIRI, CMMB, TENX, GRAY, and ASLN
Should you be buying NuCana stock or one of its competitors? The main competitors of NuCana include eFFECTOR Therapeutics (EFTR), Addex Therapeutics (ADXN), ObsEva (OBSV), Bionomics (BNOX), Cyclerion Therapeutics (CYCN), Virios Therapeutics (VIRI), Chemomab Therapeutics (CMMB), Tenax Therapeutics (TENX), Graybug Vision (GRAY), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical preparations" industry.
NuCana (NASDAQ:NCNA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations.
NuCana received 225 more outperform votes than eFFECTOR Therapeutics when rated by MarketBeat users. However, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 67.57% of users gave NuCana an outperform vote.
In the previous week, NuCana had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for NuCana and 0 mentions for eFFECTOR Therapeutics. NuCana's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.
NuCana has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.
44.0% of NuCana shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 8.4% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
NuCana currently has a consensus price target of $125.00, suggesting a potential upside of 3,096.93%. eFFECTOR Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 1,070.73%. Given NuCana's higher possible upside, equities analysts plainly believe NuCana is more favorable than eFFECTOR Therapeutics.
eFFECTOR Therapeutics' return on equity of 0.00% beat NuCana's return on equity.
NuCana has higher earnings, but lower revenue than eFFECTOR Therapeutics. NuCana is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
NuCana beats eFFECTOR Therapeutics on 8 of the 13 factors compared between the two stocks.
Get NuCana News Delivered to You Automatically
Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
